Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|August 10, 2016
The Mechanism of Action of Durvalumab in the Treatment of Urothelial Bladder Cancer
Author(s)Saeed Rafii, MD, PhD
Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.
Advertisement
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
5